Dariia Samofalova

Dariia Samofalova


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
GRGonzalo Recondo
Gonzalo Recondo
LMLaura Mezquita
Laura Mezquita
FFFrancesco Facchinetti
Francesco Facchinetti
DPDavid Planchard
David Planchard
AGAnas Gazzah
Anas Gazzah
LFLuc Friboulet
Luc Friboulet
Purpose: Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound mutations in the ALK kinase domain, other resistance mechanisms driving lorlatinib resistance remain unknown. We aimed to characterize the mechanisms of resistance to lorlatinib occurring in patients with ALK-rearranged lung cancer and design new therapeutic strategies in this setting. Experimental Design: Resistance mechanisms were investigated in 5 patients resistant to lorlatinib. Longitudinal tumor biopsies were studied using high-throughput next-generation sequencing. Patient-derived models were developed to characterize the acquired resistance mechanisms, and Ba/F3 cell mutants were generated to study the effect of novel ALK compound mutations. Drug combinatory strategies were evaluated in vitro and in vivo to overcome lorlatinib resistance. Results: Diverse biological mechanisms leading to lorlatinib resistance were identified. Epithelial–mesenchymal transition (EMT) mediated resistance in two patient-derived cell lines and was susceptible to dual SRC and ALK inhibition. We characterized three ALK kinase domain compound mutations occurring in patients, L1196M/D1203N, F1174L/G1202R, and C1156Y/G1269A, with differential susceptibility to ALK inhibition by lorlatinib. We identified a novel bypass mechanism of resistance caused by NF2 loss-of-function mutations, conferring sensitivity to treatment with mTOR inhibitors. Conclusions: This study shows that mechanisms of resistance to lorlatinib are diverse and complex, requiring new therapeutic strategies to tailor treatment upon disease progression.

15 November 2017 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
ARAlexey Rayevsky
Alexey Rayevsky
MSMohsen Sharifi
Mohsen Sharifi
DSDariia Samofalova
Dariia Samofalova
PKPavel Karpov
Pavel Karpov
YBYaroslav B. Blume
Yaroslav B. Blume

2 August 2017 in Cell Biology International
Verified
Journal Article
Closed access
PDF file
DSDariia Samofalova
Dariia Samofalova
PKPavel Karpov
Pavel Karpov
ARAlexey V. Raevsky
Alexey V. Raevsky
YBYaroslav B. Blume
Yaroslav B. Blume

5 October 2016 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
ARA. V. Raevsky
A. V. Raevsky
MSM. Sharifi
M. Sharifi
DSDariia Samofalova
Dariia Samofalova
PKPavel Karpov
Pavel Karpov
YBYaroslav B. Blume
Yaroslav B. Blume

1 July 2015 in Cytology and Genetics
Verified
Journal Article
Closed access
PDF file
DSDariia Samofalova
Dariia Samofalova
PKP. A. Karpov
P. A. Karpov
YBYa. B. Blume
Ya. B. Blume
The study presents the results of bioinformatic comparison of protein phosphatases from higher plants and human phosphatome (150 proteins). Based on sequen

17 June 2011 in Cytology and Genetics
Verified
Journal Article
Closed access
PDF file
DSDariia Samofalova
Dariia Samofalova
PKPavel Karpov
Pavel Karpov
ANA. Yu. Nuporko
A. Yu. Nuporko
YBYa. B. Blume
Ya. B. Blume
Homology modeling based on the known spatial structures of Homo sapiensprotein phosphatases types 1 and 2A was implemented. The spatial structures of human protein phosphatases and their plant...